Clematichinenoside Attenuates Myocardial Infarction in Ischemia/Reperfusion Injury both In Vivo and In Vitro

Abstract

Clematichinenoside is a triterpenoid saponin isolated from the roots of Clematis chinensis. Oxidative stress and excessive nitric oxide production are thought to play considerable roles in ischemia/reperfusion injury that impairs cardiac function. The present study investigated the protective effect of clematichinenoside on regional and global ischemia/reperfusion injury and ventricular myocytes. In vivo, regional myocardial ischemia/reperfusion injury of rats was induced by the occlusion of the left anterior descending coronary artery, and isolated guinea pigs heart using Langendorff apparatus served as a global ischemia/reperfusion injury model ex vivo. Primary cultured neonatal ventricular myocytes were further applied to explore the anti-ischemia/reperfusion injury property in vitro. Infarct size was measured with TTC stain; enzyme activities such as lactate dehydrogenase, creatine kinase, superoxide dismutase, malondialdehyde, and nitric oxide were analyzed with assay kits; inducible nitric oxide synthase and endothelial nitric oxide synthase expressions were determined by Western blot. Clematichinenoside attenuated infarct size, decreased lactate dehydrogenase, creatine kinase, and malondialdehyde levels and enhanced superoxide dismutase activity. Clematichinenoside improved hemodynamics indexes, such as left ventricular developed pressure, maximum left ventricular developed pressure, and increase/decrease rate (± dp/dt_max) in the isolated guinea pig heart after reperfusion. Clematichinenoside also inhibited excessive production of nitric oxide through downregulating inducible nitric oxide synthase as well as upregulating endothelial nitric oxide synthase during ischemia/reperfusion injury. Clematichinenoside attenuates ischemia/reperfusion injury in vivo, ex vivo, and in vitro via an antioxidant effect and by restoring the balance between inducible nitric oxide synthase and endothelial nitric oxide synthase.

Key words

clematichinenoside - myocardial ischemia/reperfusion - ventricular myocytes - oxidative stress - nitric oxide - Clematis chinensis - Ranunculaceae

^* These two authors contributed equally to this work.

• References

• 1 Guilbert JJ. The world health report 2002 – reducing risks, promoting healthy life. Educ Health (Abingdon) 2003; 16: 230
• 2 Kloner RA. Natural and unnatural triggers of myocardial infarction. Prog Cardiovasc Dis 2006; 48: 285-300
• 3 Commission CP. Pharmacopoeia of the Peopleʼs Republic of China. Beijing: Chemical Industry Press; 2005: 175
• 4 Sun SX, Li YM, Fang WR, Cheng P, Liu L, Li F. Effect and mechanism of AR-6 in experimental rheumatoid arthritis. Clin Exp Med 2010; 10: 113-121
• 5 Han W, Xiong Y, Li Y, Fang W, Ma Y, Liu L, Li F, Zhu X. Anti-arthritic effects of clematichinenoside (AR-6) on PI3K/Akt signaling pathway and TNF-α associated with collagen-induced arthritis. Pharm Biol 2013; 51: 13-22
• 6 Peng C, Perera PK, Li YM, Fang WR, Liu LF, Li FW. Anti-inflammatory effects of Clematis chinensis Osbeck extract(AR-6) may be associated with NF-κB, TNF-α, and COX-2 in collagen-induced arthritis in rat. Rheumatol Int 2012; 32: 3119-3125
• 7 Liu LF, Ma XL, Wang YX, Li FW, Li YM, Wan ZQ, Tang QL. Triterpenoid saponins from the roots of Clematis chinensis Osbeck. J Asian Nat Prod Res 2009; 11: 389-396
• 8 Ueda S, Yamagishi S, Matsui T, Jinnouchi Y, Imaizumi T. Administration of pigment epithelium-derived factor inhibits left ventricular remodeling and improves cardiac function in rats with acute myocardial infarction. Am J Pathol 2011; 178: 591-598
• 9 Long J, Gao M, Kong Y, Shen X, Du X, Son YO, Shi X, Liu J, Mo X. Cardioprotective effect of total paeony glycosides against isoprenaline-induced myocardial ischemia in rats. Phytomedicine 2012; 19: 672-676
• 10 Ibarra-Alvarado C, Rojas A, Mendoza S, Bah M, Gutierrez DM, Hernandez-Sandoval L, Martinez M. Vasoactive and antioxidant activities of plants used in Mexican traditional medicine for the treatment of cardiovascular diseases. Pharm Biol 2010; 48: 732-739
• 11 Misra MK, Sarwat M, Bhakuni P, Tuteja R, Tuteja N. Oxidative stress and ischemic myocardial syndromes. Med Sci Monit 2009; 15: RA209-RA219
• 12 Sadek HA, Humphries KM, Szweda PA, Szweda LI. Selective inactivation of redox-sensitive mitochondrial enzymes during cardiac reperfusion. Arch Biochem Biophys 2002; 406: 222-228
• 13 Piao CS, Gao S, Lee GH, Kim do S, Park BH, Chae SW, Chae HJ, Kim SH. Sulforaphane protects ischemic injury of hearts through antioxidant pathway and mitochondrial K_ATP channels. Pharmacol Res 2010; 61: 342-348
• 14 Fu J, Huang H, Liu J, Pi R, Chen J, Liu P. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 2007; 568: 213-221
• 15 Maehata Y, Miyagawa S, Sawa Y. Activated protein C has a protective effect against myocardial I/R injury by improvement of endothelial function and activation of AKT1. PLoS One 2012; 7: e38738
• 16 Zhang Y, Wei L, Sun D, Cao F, Gao H, Zhao L, Du J, Li Y, Wang H. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes Obes Metab 2010; 12: 316-322
• 17 Wattanapitayakul SK, Bauer JA. Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. Pharmacol Ther 2001; 89: 187-206
• 18 Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-1131
• 19 Otani H. The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal 2009; 11: 1913-1928
• 20 Houshmand F, Faghihi M, Zahediasl S. Biphasic protective effect of oxytocin on cardiac ischemia/reperfusion injury in anaesthetized rats. Peptides 2009; 30: 2301-2308
• 21 Peng J, Xiao J, Ye F, Deng HW, Li YJ. Inhibition of cardiac tumor necrosis factor-α production by calcitonin gene-related peptide-mediated ischemic preconditioning in isolated rat hearts. Eur J Pharmacol 2000; 407: 303-308
• 22 Germack R, Griffin M, Dickenson JM. Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes. J Mol Cell Cardiol 2004; 37: 989-999
• 23 Fang W, Deng Y, Li Y, Shang E, Fang F, Lv P, Bai L, Qi Y, Yan F, Mao L. Blood brain barrier permeability and therapeutic time window of Ginkgolide B in ischemia-reperfusion injury. Eur J Pharm Sci 2010; 39: 8-14
• 24 Takano H, Manchikalapudi S, Tang XL, Qiu Y, Rizvi A, Jadoon AK, Zhang Q, Bolli R. Nitric oxide synthase is the mediator of late preconditioning against myocardial infarction in conscious rabbits. Circulation 1998; 98: 441-449
• 25 Deng Y, Fang W, Li Y, Cen J, Fang F, Lv P, Gong S, Mao L. Blood-brain barrier breakdown by PAF and protection by XQ-1H due to antagonism of PAF effects. Eur J Pharmacol 2009; 616: 43-47